Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CCL2 | P13500 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10176664 | 0.86 | PDIA6 (0.41) | MAOADYRK1AHPGDPDIA6KDM4E | |
| SCHEMBL8257891 | 0.85 | MAOA (0.39) | MAOADYRK1AHPGDKDM4ETDP1 | |
| SCHEMBL19532820 | 0.83 | SMN1; SMN2 (0.46) | MAOAPDIA6ALOX5DRD2DRD4 | |
| SCHEMBL19532813 | 0.81 | KDR (0.40) | MAOADYRK1ALMNAMAPK1HTT | |
| SCHEMBL17688873 | 0.80 | NQO1 (0.48) | HPGDKDM4ETDP1LMNACA1 | |
| SCHEMBL20328579 | 0.80 | NR5A1 (0.49) | PDIA6 | |
| SCHEMBL8256675 | 0.80 | HPGD (0.55) | MAOADYRK1AHPGDPDIA6KDM4E | |
| SCHEMBL19504075 | 0.78 | PDIA6 (0.46) | PDIA6KDM4ETDP1DRD2DRD4 | |
| SCHEMBL21718948 | 0.78 | LMNA (0.40) | MAOADYRK1AKDM4ETDP1DRD2 | |
| SCHEMBL21718856 | 0.78 | FBP1 (0.36) | MAOADYRK1APDIA6KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206903-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206903-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | MAOA 2312/4885DYRK1A 4711/4885HPGD 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.